Business Context and Reporting Period
This Form 8-K Current Report was filed by India Globalization Capital, Inc. (IGC Pharma, Inc.) on September 12, 2018. The filing discloses the entry into a material definitive agreement regarding a private placement of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of common stock.
- Shares Issued: 869,565 shares of restricted common stock.
- Total Purchase Price: $1,000,000.
- Price Per Share: $1.15.
- Post-Transaction Outstanding Shares: Approximately 33,255,266 shares.
- Registration Status: Unregistered, relying on Section 4(a)(2) exemption of the Securities Act of 1933.
The filing does not provide specific data on revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
The primary material change is the increase in outstanding common stock and the influx of capital from the sale of 869,565 shares. The transaction is subject to customary closing conditions, including approval by the NYSE.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the anticipated closing of the offering. Management notes that risks and uncertainties are detailed in the company's Form 10-K and Form 10-Q filings. The investor has been granted piggyback registration rights subject to certain restrictions.
Investor Verification Checklist
- Verify the final closing of the transaction and receipt of the $1,000,000 proceeds.
- Confirm NYSE approval for the issuance of the new shares.
- Review the full text of the Q2 2019 Stock Purchase Agreement (Exhibit 10.1) for specific covenants and restrictions.
- Check subsequent filings for the updated share count and capitalization table.